Vedolizumab | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Vedolizumab
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

Vedolizumab

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

5 API Suppliers, 2 NDC API, 3 Listed Suppliers

5 API Suppliers
2 NDC API
3 Listed Suppliers

DEVELOPMENTS

80 Drugs in Development

80 Drugs in Development

FINISHED DOSAGE FORMULATIONS

27 FDF Dossiers, 5 FDA Orange Book, 4 Europe, 3 Canada, 14 Australia, 1 South Africa

27 FDF Dossiers
5 FDA Orange Book
4 Europe
3 Canada
14 Australia
1 South Africa

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 66 News #PharmaBuzz

1 Data Compilation #PharmaFlow
66 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 3 Regulatory FDF Prices, 9 Annual Reports

2 US Medicaid Prescriptions
3 Regulatory FDF Prices
9 Annual Reports

PATENTS & EXCLUSIVITIES

11 Health Canada Patents

11 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

11 All

01 9Gowling WLG

02 2Gowling WLG (Canada) LLP

filter Patent Reset all filters

11 All

01 12212702

02 12263106

03 32834867

04 22834900

05 13028209

06 33051418

filter Product Reset all filters

11 All

01 11VEDOLIZUMAB

filter Dosage Reset all filters

11 All

01 5POWDER FOR SOLUTION

02 6SOLUTION

filter Exp Date Reset all filters

11 All

01 12016-02-12

02 12017-08-06

03 92032-05-02

Product Main Page

01

Gowling WLG (Canada) LLP

VEDOLIZUMAB

ChemOutsourcing

Not Confirmed

Gowling WLG (Canada) LLP

Canada

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2017-08-06

Date Granted : 2010-08-03

VEDOLIZUMAB

Brand Name : ENTYVIO

Patent Number : 2263106

Filing Date : 1997-08-06

Strength per Unit : 300mg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2017-08-06

Date Granted : 2010-08-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowling WLG (Canada) LLP

VEDOLIZUMAB

ChemOutsourcing

Not Confirmed

Gowling WLG (Canada) LLP

Canada

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2016-02-12

Date Granted : 2010-04-20

VEDOLIZUMAB

Brand Name : ENTYVIO

Patent Number : 2212702

Filing Date : 1996-02-12

Strength per Unit : 300mg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2016-02-12

Date Granted : 2010-04-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Gowling WLG

VEDOLIZUMAB

ChemOutsourcing

Not Confirmed

Gowling WLG

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-02

Date Granted : 2019-02-12

VEDOLIZUMAB

Brand Name : ENTYVIO

Patent Number : 2834867

Filing Date : 2012-05-02

Strength per Unit : 300mg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2032-05-02

Date Granted : 2019-02-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Gowling WLG

VEDOLIZUMAB

ChemOutsourcing

Not Confirmed

Gowling WLG

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-02

Date Granted : 2021-01-05

VEDOLIZUMAB

Brand Name : ENTYVIO

Patent Number : 3028209

Filing Date : 2012-05-02

Strength per Unit : 300mg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2032-05-02

Date Granted : 2021-01-05

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Gowling WLG

VEDOLIZUMAB

ChemOutsourcing

Not Confirmed

Gowling WLG

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-02

Date Granted : 2021-03-02

VEDOLIZUMAB

Brand Name : ENTYVIO

Patent Number : 2834900

Filing Date : 2012-05-02

Strength per Unit : 108 mg / 0.68 mL (pre - filled Syringe)

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2032-05-02

Date Granted : 2021-03-02

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Gowling WLG

VEDOLIZUMAB

ChemOutsourcing

Not Confirmed

Gowling WLG

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-02

Date Granted : 2021-03-02

VEDOLIZUMAB

Brand Name : ENTYVIO

Patent Number : 2834900

Filing Date : 2012-05-02

Strength per Unit : 108 mg / 0.68 mL (pre - filled pen)

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2032-05-02

Date Granted : 2021-03-02

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

Gowling WLG

VEDOLIZUMAB

ChemOutsourcing

Not Confirmed

Gowling WLG

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-02

Date Granted : 2021-05-18

VEDOLIZUMAB

Brand Name : ENTYVIO

Patent Number : 3051418

Filing Date : 2012-05-02

Strength per Unit : 300mg / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2032-05-02

Date Granted : 2021-05-18

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

Gowling WLG

VEDOLIZUMAB

ChemOutsourcing

Not Confirmed

Gowling WLG

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-02

Date Granted : 2019-02-12

VEDOLIZUMAB

Brand Name : ENTYVIO

Patent Number : 2834867

Filing Date : 2012-05-02

Strength per Unit : 108 mg / 0.68 mL (pre - filled Syringe)

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2032-05-02

Date Granted : 2019-02-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

09

Gowling WLG

VEDOLIZUMAB

ChemOutsourcing

Not Confirmed

Gowling WLG

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-02

Date Granted : 2021-05-18

VEDOLIZUMAB

Brand Name : ENTYVIO

Patent Number : 3051418

Filing Date : 2012-05-02

Strength per Unit : 108 mg / 0.68 mL (pre - filled Syringe)

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2032-05-02

Date Granted : 2021-05-18

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

10

Gowling WLG

VEDOLIZUMAB

ChemOutsourcing

Not Confirmed

Gowling WLG

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-05-02

Date Granted : 2019-02-12

VEDOLIZUMAB

Brand Name : ENTYVIO

Patent Number : 2834867

Filing Date : 2012-05-02

Strength per Unit : 108 mg / 0.68 mL (pre - filled pen)

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2032-05-02

Date Granted : 2019-02-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!